Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New study reveals how to improve chemotherapy use in prostate cancer

17.02.2015

Next generation chemotherapy for prostate cancer has unique properties that could make it more effective earlier in treatment if confirmed in clinical trials

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease.

A study published online this week (January 17th) in Clinical Cancer Research, researchers have found that a newer member of the taxane family called cabazitaxel, an FDA approved drug, has properties that could make it more effective for some patients - a hypothesis currently being tested in clinical trials. Researchers also found a genomic marker that could help physicians identify which patients might benefit most from cabazitaxel.

"It was surprising to find that cabazitaxel functions differently than docetaxel in killing cancer cells, even though they're both taxanes," says senior author Karen Knudsen, Ph.D., Interim Director of the Sidney Kimmel Cancer Center and a professor of cancer biology at the Sidney Kimmel Medical College at Thomas Jefferson University. "It shows that we may not be taking full advantage of this next generation taxane in the clinic."

For years, docetaxel has been the only effective chemotherapy for men whose cancer was no longer responding to hormone treatments. The next generation drug in the taxane family, cabazitaxel, was approved in 2010, but only for patients whose cancer no longer responded to hormone therapy or docetaxel treatment.

Knudsen and colleagues explored how cabazitaxel worked and demonstrated that it might be more effective sooner in treatment. The researchers showed that cabazitaxel worked better than docetaxel in human prostate cancer cells lines that were resistant hormone treatment, both in terms of slowing cancer-cell growth and in its ability to kill cancer cells. Analysis of the tumor genes affected by the two drugs revealed that cabazitaxel had a greater effect on cellular division and regulation of chromatin - a spool for DNA that helps control which genes are in use and when - whereas docetaxel has a greater impact on DNA transcription and repair. "This difference in mechanism suggests that we should treat these two drugs less like members of the same family, and more like two distinct therapies that may each have distinct benefits for certain patients," says first author Renée de Leeuw, a postdoctoral researcher in the department of cancer biology at Thomas Jefferson University.

In order to test their hypothesis in a model that more closely mimicked human disease, the researchers also tested the two drugs side-by-side on slices of tumors removed from patients during radical prostatectomy. The tissues were grown on a 3D gelatin sponge, and two portions of the same tumor were treated with either cabazitaxel or docetaxel. The results confirmed that cabazitaxel was more effective at killing tumor cells than docetaxel. "The ability to test our ideas in tumor tissues removed from patients underscores the unique and multi-disciplinary nature of our Prostate Cancer Program, one of only eight Prostate Cancer Programs of Excellence in National Cancer Institute Designated Centers," said Dr. Knudsen. "Notably, key contributors to the study included leaders in Urology, Medical Oncology and Radiation Oncology, Drs. Leonard Gomella, W. Kevin Kelly, and Adam Dicker."

The collaborative research team also found a molecular marker that would help identify patients most likely to benefit from cabazitaxel treatment. Knudsen and colleagues showed that tumors whose retinoblastoma (RB) gene no longer worked were likely to become hormone resistant, but remarkably were more likely to respond to cabazitaxel. "This gene could give us a way to identify patients who would benefit from cabazitaxel earlier and reduce the trial and error of treating a cancer patient," says Dr. Knudsen.

Drs. Kelly and Knudsen are testing their hypothesis in a phase II clinical trial (ABICABAZI NCT02218606), currently recruiting patients. The study is funded by Sanofi and conducted as a collaboration between Sidney Kimmel Cancer Center and Memorial-Sloan Kettering Cancer Center. Patients with metastatic prostate cancer who have not yet been treated with chemotherapy will be given either the second-line hormone therapy abiraterone, or abiraterone in combination with cabazitaxel. In addition, researchers will scan the tumors for their RB gene expression to test whether low levels of RB correlate with strong responses to cabazitaxel.

"These results from our laboratory research give us a strong reason to believe that this drug could be more useful to some men earlier in their course of treatment," says Dr. Knudsen. "The ABICABAZI trial puts these ideas to the test in humans, and if we are correct, has the capacity for the first time to tell us what patients might most benefit from chemotherapy."

###

This work was supported, in whole or in part by a Department of Defense PCRP postdoctoral award (FY2012 PC121719), a National Institute of Health grant K01 OD010463, a Prostate Cancer Foundation Young Investigator Award, a Sanofi-Aventis grant, NIH grants (R01 CA099996-11, CA159945-03, CA176401-01A1), and a Commonwealth of Pennsylvania Cure grant (SAP# 41000548782). The authors report no other conflicts of interest.

For more information, contact Edyta Zielinska, 215-955-5291, edyta.zielinska@jefferson.edu.

About Jefferson -- Health is all we do.

Thomas Jefferson University, Thomas Jefferson University Hospitals and Jefferson University Physicians are partners in providing the highest-quality, compassionate clinical care for patients, educating the health professionals of tomorrow, and discovering new treatments and therapies that will define the future of healthcare. Thomas Jefferson University enrolls more than 3,600 future physicians, scientists and healthcare professionals in the Sidney Kimmel Medical College (SKMC); Jefferson Schools of Health Professions, Nursing, Pharmacy, Population Health; and the Graduate School of Biomedical Sciences, and is home of the National Cancer Institute (NCI)-designated Sidney Kimmel Cancer Center. Jefferson University Physicians is a multi-specialty physician practice consisting of over 650 SKMC full-time faculty. Thomas Jefferson University Hospitals is the largest freestanding academic medical center in Philadelphia. Services are provided at five locations -- Thomas Jefferson University Hospital and Jefferson Hospital for Neuroscience in Center City Philadelphia; Methodist Hospital in South Philadelphia; Jefferson at the Navy Yard; and Jefferson at Voorhees in South Jersey.

Edyta Zielinska | EurekAlert!

Further reports about: CANCER Chemotherapy cancer cells hormone prostate prostate cancer tumors

More articles from Studies and Analyses:

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

nachricht Europe’s Demographic Future. Where the Regions Are Heading after a Decade of Crises
10.08.2017 | Berlin-Institut für Bevölkerung und Entwicklung

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tiny lasers from a gallery of whispers

New technique promises tunable laser devices

Whispering gallery mode (WGM) resonators are used to make tiny micro-lasers, sensors, switches, routers and other devices. These tiny structures rely on a...

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

“Lasers in Composites Symposium” in Aachen – from Science to Application

19.09.2017 | Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

 
Latest News

Molecular Force Sensors

20.09.2017 | Life Sciences

Producing electricity during flight

20.09.2017 | Power and Electrical Engineering

Tiny lasers from a gallery of whispers

20.09.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>